Conclusion: These data highlight the importance of turning the "best practice policies" readily available to all pediatric oncologists. Local protocols allow integrative studies among centers that would certainly maintain or improve cure rates, reduce long-term toxicity and evaluate specific biological characteristics of these diseases in our population. For these reasons, we reinforce the idea that standardization of treatment in pediatric oncology is a child health priority and also a viable low-cost strategy to improve care in middle-income countries such as Brazil .
INTRODUCTION
Many times, improvement in healthcare focuses in the use of new drugs. In fact, in many situations this is the most reliable and important measure available. Recently, in pediatric oncology there was an increase in the use of immunotherapy as a therapeutic choice in different diseases. Although they are very effective, their prices are frequently high which makes them a significant spent in middle income countries that have many other essentials health issues to be addressed. To rationalize the use of these new agents and indicate them correctly, one must be sure that an effective first-line treatment is being used. It is also important to notice that through the years the Brazilian population benefits of a unified health system (SUS) that allows access to most treatment. In this reality, children with cancer can have access to Pediatric Oncology Centers through a local network. Unfortunately, data about treatment, evolution and long-term effects are not routinely recorded.
In this context, we looked for one important marker of quality of care in pediatric oncology assistance: the use of protocols or, in their absence, clinical practice guidelines. Although there is no national guideline, Hodgkin disease (HD) is a neoplasia that has a standard of care with chemotherapeutic agents available in Brazil and good international results. In our study, we were able to conclude that there was a high inter-institutional heterogeneity of treatment but also there was not a standard treatment inside each institution.
Methods
This is a descriptive retrospective study based on medical records and the following data were analyzed: age at diagnosis, sex, stage, presence of Bulky disease at diagnosis, therapeutic regimen, first treatment response, relapse, high dose chemotherapy regimen and radiotherapy. were included in this study. The study followed institutional ethical guidelines.
Patients were staged according Ann Arbor staging criteria and the presence of B symptoms (fever greater than 38°C for at least 3 consecutive days, night sweats and unexplained weight loss greater than 10% of body weight within the last 6 months). The procedures used for staging were clinical history, physical exam, CT scans (neck, chest and abdomen), gallium scintigraphy and bone marrow biopsy.
The schema of chemotherapy and radiotherapy received was registered, as well as response and status.
Results

Fifty-nine children and adolescents registered in six different pediatric oncology centers in South
Brazil with diagnosis of HD were included. The median age was 12 years (range 3-18 years). (Table 1) .
Radiation therapy was used in 34 patients (58.6%). As described in Table 1 , this indication did not follow stage or remission criteria. In this cohort three (5%) patients died, one of treatment related toxicity and 2 of disease progression.
DISCUSSION
HL is a paradigm in pediatric oncology since the goal of treatment is not only to heal but also to guarantee quality of life and social insertion for these children. Through our study, we were able to conclude that treatment in our reality was highly heterogeneous among institutions but also that there was not a standard of care even inside each institution ¹. Our study represents a small sample of children with a specific disease (HD) from only one state in Brazil and did not evaluate the use of clinical and radiological criteria of stage and response. We can assume that discrepancies are even greater among different regions of our country with lower socio-cultural status or less access to health system and that they are probably not restricted to HD.
It is widely described that patients that are enrolled and followed up in a protocol of treatment have better prognosis and probably less adverse effects than those who are not ². We also know that networking is fundamental to facilitate access to exams and research, but also to allow a better comprehension of the local reality ³. Although we have shown in our study that survival rate in our population is similar to those described in international studies, we can infer from these data that some children received an excessive treatment leading to a possible long-term toxicity.
These data highlight the importance of turning the "best practice policies" readily available to all pediatric oncologists. Local protocols allow integrative studies among centers that would certainly maintain or improve cure rates, reduce long-term toxicity and evaluate specific biological characteristics of neoplasias in our population. For these reasons, we reinforce the idea that standardization of treatment in pediatric oncology is a child health priority and a viable lowcost strategy to improve care in middle-income countries such as Brazil 4, 5 . 
